David J Lloyd

List of Publications by Year in descending order

35 papers	3,975 citations	279701 23 h-index	395590 33 g-index
36 all docs	36 docs citations	36 times ranked	5345 citing authors

#	Article	IF	Citations
1	GIPR gene expression in testis is mouse specific and can impact male mouse fertility. Andrology, 2022, , .	1.9	0
2	GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. Cell Reports Medicine, 2021, 2, 100263.	3.3	30
3	Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?. Endocrine Reviews, 2020, 41, 1-21.	8.9	55
4	Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor. MAbs, 2020, 12, 1710047.	2.6	7
5	Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nature Communications, 2020, 11, 4981.	5.8	57
6	Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Science Translational Medicine, 2018, 10, .	5.8	136
7	Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes. Diabetes, 2016, 65, 1434-1446.	0.3	18
8	Small Molecule Disruptors of the Glucokinaseâ€“Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis. Journal of Medicinal Chemistry, 2015, 58, 4462-4482.	2.9	23
9	Pharmacologic Effects of FGF21 Are Independent of the â€œBrowningâ€•of White Adipose Tissue. Cell Metabolism, 2015, 21, 731-738.	7.2	172
10	Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinaseâ€“Glucokinase Regulatory Protein (GKâ€“GKRP) Binding: Strategic Use of a N â†' S (n_N â†' Ïƒ*_{Sâ€“X}) Interaction for Conformational Constraint. Journal of Medicinal Chemistry, 2015, 58, 9663-9679.	2.9	33
11	Molecular targeting of the GK-GKRP pathway in diabetes. Expert Opinion on Therapeutic Targets, 2015, 19, 129-139.	1.5	19
12	A Gain-of-Function Mutation in Adenylate Cyclase 3 Protects Mice from Diet-Induced Obesity. PLoS ONE, 2014, 9, e110226.	1.1	44
13	A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice. Lipids in Health and Disease, 2014, 13, 167.	1.2	14
14	Small Molecule Disruptors of the Glucokinaseâ€“Glucokinase Regulatory Protein Interaction: 3. Structureâ€“Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-Nâ€²-arylpiperazine Series. Journal of Medicinal Chemistry, 2014, 57, 3094-3116.	2.9	46
15	Small Molecule Disruptors of the Glucokinaseâ€“Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept. Journal of Medicinal Chemistry, 2014, 57, 309-324.	2.9	29
16	Small Molecule Disruptors of the Glucokinaseâ€“Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles. Journal of Medicinal Chemistry, 2014, 57, 325-338.	2.9	22
17	Small Molecule Disruptors of the Glucokinaseâ€“Glucokinase Regulatory Protein Interaction: 4. Exploration of a Novel Binding Pocket. Journal of Medicinal Chemistry, 2014, 57, 5949-5964.	2.9	11
18	Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature, 2013, 504, 437-440.	13.7	94

#	Article	IF	Citations
19	FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice. PLoS ONE, 2012, 7, e40164.	1.1	127
20	A Volumetric Method for Quantifying Atherosclerosis in Mice by Using MicroCT: Comparison to En Face. PLoS ONE, 2011, 6, e18800.	1.1	21
21	Pharmacological Targeting of Glucagon and Glucagon-Like Peptide 1 Receptors Has Different Effects on Energy State and Glucose Homeostasis in Diet-Induced Obese Mice. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 70-81.	1.3	29
22	A Point Mutation in Sec61Î±1 Leads to Diabetes and Hepatosteatosis in Mice. Diabetes, 2010, 59, 460-470.	0.3	60
23	Loss-of-Function Mutation in Myostatin Reduces Tumor Necrosis Factor Î± Production and Protects Liver Against Obesity-Induced Insulin Resistance. Diabetes, 2009, 58, 1133-1143.	0.3	139
24	Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice. Journal of Lipid Research, 2009, 50, 534-545.	2.0	3
25	Antidiabetic effects of 11Î²â€HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes, Obesity and Metabolism, 2009, 11, 688-699.	2.2	34
26	New Variants in the Enpp1 and Ptpn6 Genes Cause Low BMD, Crystal-Related Arthropathy, and Vascular Calcification. Journal of Bone and Mineral Research, 2009, 24, 1552-1564.	3.1	36
27	Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice. Diabetes, 2009, 58, 250-259.	0.3	970
28	Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice. Human Molecular Genetics, 2008, 17, 3435-3435.	1.4	0
29	Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48^{â^'/â^'}Lep^{ob/ob}mice devoid of ApoE or Ldlr. American Journal of Physiology - Endocrinology and Metabolism, 2008, 294, E496-E505.	1.8	30
30	Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice. Human Molecular Genetics, 2006, 15, 1884-1893.	1.4	126
31	SUN1 Interacts with Nuclear Lamin A and Cytoplasmic Nesprins To Provide a Physical Connection between the Nuclear Lamina and the Cytoskeleton. Molecular and Cellular Biology, 2006, 26, 3738-3751.	1.1	440
32	Diabetes Insipidus in Mice with a Mutation in Aquaporin-2. PLoS Genetics, 2005, 1, e20.	1.5	61
33	A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Human Molecular Genetics, 2002, 11, 769-777.	1.4	271
34	Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes, 2000, 49, 1958-1962.	0.3	165
35	LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nature Genetics, 2000, 24, 153-156.	9.4	653